Novo Nordisk is buying Cardior Pharmaceuticals for around $1 billion as it strengthens its pipeline of drugs to treat cardiovascular disease and expand into areas outside of its core diabetes and weight-loss market.
Novo Nordisk is buying Cardior Pharmaceuticals for around $1 billion as it strengthens its pipeline of drugs to treat cardiovascular disease and expand into areas outside of its core diabetes and weight-loss market.